Medicure Inc (TSE:MPH)
:MPH
Want to see TSE:MPH full AI Analyst Report?
MPH Stock Chart & Stats
C$1.25
C$0.01(1.22%)
At close: 4:00 PM EST
C$1.25
C$0.01(1.22%)
Day’s Range― - ―
52-Week RangeC$0.82 - C$1.43
Previous CloseN/A
Volume1.00K
Average Volume (3M)1.72K
Market Cap
C$9.39M
Enterprise ValueC$6.97M
Total Cash (Recent Filing)C$3.83M
Total Debt (Recent Filing)C$891.00K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,436,313
10 Day Avg. Volume717
30 Day Avg. Volume1,717
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.92
Price to Sales (P/S)0.41
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low-debt Balance SheetVery low debt provides durable financial flexibility: it reduces bankruptcy risk, preserves borrowing capacity for clinical or commercial funding, and allows management to prioritize product commercialization or targeted R&D without immediate pressure to refinance, relevant over the next 2–6 months.
Top-line MomentumSustained revenue growth indicates underlying demand for marketed cardiovascular products and validates commercial execution. Over a multi-month horizon this trend supports recovery of operating leverage, potential scale benefits, and a clearer path to restoring profitability if maintained.
Focused Specialty Commercial ModelA narrow specialty focus yields durable advantages: targeted sales force expertise, deeper payer/provider relationships, and predictable prescription revenues. This specialization supports defensibility in chosen niches and easier prioritization of resources for commercialization and development over coming months.
Bears Say
Worsening ProfitabilityA materially larger net loss signals weaker earnings power and negative operating leverage. Persisting losses erode retained earnings, limit reinvestment capacity into commercialization or pipeline activities, and increase reliance on external funding unless margins and cost structure improve.
Negative Operating And Free Cash FlowA shift to negative operating and free cash flow raises funding risk: core operations no longer self-fund growth or R&D. Over the medium term this increases the likelihood of dilutive financing or constrained commercial investment, making execution on strategy more difficult.
Equity Erosion Reduces Capital CushionA sharp drop in equity shrinks the capital buffer available to absorb future losses or fund strategic initiatives. Even with low debt, reduced equity limits the company's resilience to setbacks, may raise lender scrutiny, and can constrain partnership or licensing options over the next several months.
Medicure News
MPH FAQ
What was Medicure Inc’s price range in the past 12 months?
Medicure Inc lowest stock price was C$0.82 and its highest was C$1.43 in the past 12 months.
What is Medicure Inc’s market cap?
Medicure Inc’s market cap is C$9.39M.
When is Medicure Inc’s upcoming earnings report date?
Medicure Inc’s upcoming earnings report date is Jun 02, 2026 which is in 35 days.
How were Medicure Inc’s earnings last quarter?
Currently, no data Available
Is Medicure Inc overvalued?
According to Wall Street analysts Medicure Inc’s price is currently Overvalued.
Does Medicure Inc pay dividends?
Medicure Inc does not currently pay dividends.
What is Medicure Inc’s EPS estimate?
Medicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure Inc have?
Medicure Inc has 10,436,313 shares outstanding.
What happened to Medicure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medicure Inc?
Currently, no hedge funds are holding shares in TSE:MPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Technical Analysis
Aequus Pharmaceuticals
―
Pharmadrug
―
Mountain Valley MD
―
Medexus Pharmaceuticals Inc
―
Xebra Brands Ltd.
―